CRISPR‐based detection of Helicobacter pylori in stool samples

Abstract

Helicobacter pylori (H. pylori) is a helical, gram-negative, microaerophilic bacterium that is responsible for several gastroduodenal diseases, such as chronic gastritis, peptic ulcer, gastric mucosaassociated lymphoid tissue (MALT), and gastric adenocarcinoma. 1 It is estimated that more than 50% of the global population is infected with H. pylori, and it could be worse in developing countries given that the prevalence of H. pylori may be correlated with socioeconomic status. 2,3 It is widely known that H. pylori infection can be diagnosed by invasive and noninvasive methods. Noninvasive methods, such as the urea breath test and serological test, are widely applied in clinical practice. However, almost all the commonly used noninvasive

Rapid detection of HPV16/18 based on a CRISPR-Cas13a/Cas12a dual-channel system

“…The sensitivity of the RAA-based multiplex CRISPR-Cas13a/Cas12a dual virus assay was comparable to that of other CRISPR assays, such as the detection of novel coronavirus, hepatitis B virus, Ebola virus, Mycobacterium tuberculosis, and Helicobacter pylori. [50][51][52][53][54] However, this semi-quantitative assay relies on a real-time uorescence quantitative PCR instrument, which limits its application in the eld. In light of emerging or re-emerging infectious diseases, food contamination, and environmental pollution, there is an urgent need to develop new nucleic acid detection technologies with higher sensitivity and specicity, especially for point-of-care testing (POCT) in the eld.…”

Rapid and Sensitive Assay of Helicobacter pylori With One-Tube RPA-CRISPR/Cas12 by Portable Array Detector for Visible Analysis of Thermostatic Nucleic Acid Amplification

“…At present, many CRISPR-based molecular diagnostics are relying on paper-based signal outputs. Although these paper-based methods do not require any large equipment to read the assay results, they have a much lower limit of detection formula than fluorescent signal-based assays ( Qiu et al, 2021 ). In contrast, many CRISPR-based fluorescence output detection platforms still require large blue light transilluminators, which cannot be widely used for point-of-care testing and distributed operations.…”

Powerful CRISPR-Based Biosensing Techniques and Their Integration With Microfluidic Platforms

“…Supported by automated microfluidic mixing, an approach for Ebola virus detection was established using Cas13a and achieved an LoD of 20 pfu/ ml (5.45 × 10 7 copies/ml) of purified Ebola RNA within 5 min (Qin et al, 2019). Cas12a-based biosensing was also developed for the detection of a variety of pathogenic microorganisms, such as Listeria monocytogenes , Cryptosporidium parvum (Yu et al, 2021), Salmonella (Ma et al, 2021), Helicobacter pylori (Qiu et al, 2021), Yersinia pestis (You et al, 2021), E. coli, and Staphylococcus aureus (Bonini et al, 2021). Coupling with a reversible valve-assisted chip, sample preparation, Cas12a reactions, and LAMP was integrated and controlled precisely to perform the detection of V. parahaemolyticus, achieving an LoD of 30 copies/reaction within 50 min (Wu et al, 2021b).…”